Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis

Enrico Maria Zardi, Antonio Picardi, Giovanni Ambrosino, Vito Michele Fazio, Aldo Dobrina, Mauro Frego, Antonella Afeltra, Franco Lumachi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Iloprost, a prostacyclin analog, reduces hepatic microcirculatory damage after ischemia-reperfusion injury in animal liver models. The objective of this study was to evaluate whether the portal flow velocity changes after Iloprost infusion in patients with systemic sclerosis and Raynaud's phenomenon, who usually have increased risk of microvascular thrombosis and transient liver disturbances. Patients and Methods: Fifteen patients (3 males and 12 females, median age 58 years, range 47-66 years), with systemic sclerosis and Raynaud's phenomenon, were exclusively treated with an infusion of Iloprost (2 ng/ kg/min, 6 h/day) for 5 days. In each subject, the portal flow velocity (PV, cm/sec) and portal flow volume (PFV, mL/min) were obtained by using portal color Doppler ultrasonography equipment. Results: Iloprost admin istration significantly (p

Original languageEnglish
Pages (from-to)377-380
Number of pages4
JournalIn Vivo
Volume20
Issue number3
Publication statusPublished - May 2006

Keywords

  • Color Doppler ultrasonography
  • Hepatic microcircle
  • Iloprost
  • Portal flow
  • Raynaud's phenomenon
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis'. Together they form a unique fingerprint.

Cite this